Boston Scientific Acquires Bolt Medical for $443 Million

Boston Scientific has announced a strategic acquisition. The company will purchase the remaining 74% stake in Bolt Medical for approximately $443 million, which is likely to impact stock prices. This move is expected to benefit Boston Scientific in the long run.

Date: 08-01-2025

AI Rating: 6

Earnings Per Share (EPS): The acquisition is indicated to be slightly dilutive to adjusted earnings per share in 2025. This suggests a possible impact on the earnings of Boston Scientific in the near future.

Revenue Growth: The potential for revenue growth stems from Bolt Medical’s innovative IVL platform, which could enhance Boston Scientific’s offerings in the cardiovascular market.

Net Income, Profit Margins, Free Cash Flow, Return on Equity: There are no specific mentions or data regarding Net Income, Profit Margins, Free Cash Flow, or Return on Equity in the report, so analysis on these areas cannot be provided.

The total acquisition cost includes potential additional payments amounting to $221 million based on regulatory achievements, indicating further investment risk but potentially rewarding returns if successful. The stock price has already seen an uptick of 2.07% in pre-market trading, suggesting positive investor sentiment ahead of this announcement.

Stocks: BSX